Abstract: A continuous production system for fabricating composite articles from a moldable material includes, in an exemplary embodiment, a pair of opposed closed loop cleated belt conveyors spaced apart a predetermined distance. Each cleated belt includes a plurality of cleats, and each cleat includes a notch. The forming system also includes a pair of opposed endless profile mold belts positioned at least partially between the pair of cleated belts. The mold belts are located at least partially in the notches of the cleats.

Abstract: The present invention features methods of treating a cancer in a subject by administering an effective amount of a beta-lactone to the subject. The invention also features methods of inhibiting angiogenesis in a subject by administering an effective amount of an inhibitor of fatty acid synthase to the subject. These methods can be used to treat a variety of cancers and other diseases and conditions. The invention also features methods of identifying beta-lactones and other compounds that can be used in the methods of the invention for the treatment of tumors, inhibition of angiogenesis, and the treatment of diseases and conditions that involve pathological angiogenesis. The invention also features methods of synthesizing beta-lactones and features novel beta-lactone compounds.

Abstract: Discovered is a novel protein and variants thereof whose activity at the NMDA receptor causes an increased efflux of calcium ions through the channel of said receptor. This activity is downregulated by the NR3A subunit of NMDA. Also discovered are the nucleic acid sequences encoding said novel protein and variants thereof. The discovery is useful for the diagnosing of NMDA receptor dysregulation and the treatment of NMDA receptor dysregulation related disorders. In addition, the discovery is useful for the further discovery of modulators affecting the activity of the novel protein and variants thereof at the NMDA receptor.

Abstract: The use of ?-adrenergic inverse agonists provides a new and highly efficient way of treating a number of pulmonary airway diseases, including asthma, emphysema, and chronic obstructive pulmonary diseases. In general, such a method involves administering a therapeutically effective amount of a ?-adrenergic inverse agonist to the subject to treat the pulmonary airway disease. Particularly preferred inverse agonists include nadolol and carvedilol. In addition, methods are described for long-tern administration of such inverse agonists and for determining the suitability of patients for long-term inverse agonist therapy.

Abstract: A novel human member of the Bcl-2 family Bcl-B has been identified, which is closest in amino-acid sequence homology to the Boo (Diva) protein. The Bcl-B protein is widely expressed in adult human tissues. The Bcl-B protein modulates apoptosis. Bcl-B also binds Bcl-2, BCI-XL, and Bax but not Bak. Bcl-B displays a unique pattern of selectivity for binding and regulating the function of other members of the Bcl-2 family.

Abstract: The present invention relates to novel methods for identifying antiviral agents which selectively interfere with viral proteins that cause the unique infectivity activity of the SARS-coronavirus in comparison to other non-SARS strains of coronavirus. In particular, the present invention relates to screening assays that identify agents which selectively inhibit cyclic-AMP dependent protein kinase activity of the SARS-coronavirus ORF3. The present invention also relates to screening assays that identify agents which selectively inhibit the interaction between SARS-coronavirus cyclic-AMP dependent protein kinase and a calcium dependent targeting molecule. Therefore the agents identified using the assays of the invention may have utility as antiviral agents. The present invention also relates to treatments for sever acute respiratory syndrome caused by a coronavirus, and particularly to treatments that affect the infectivity activity of the SARS-coronavirus.

Abstract: A kit for obtaining an endoarterial biopsy sample from a patient including packaging material enclosing one or more kit components; the kit components include instruments use to perform a surgical procedure; and the kit includes separate phase specific packaging parts.

Abstract: A new method is described for the treatment of cancer. In one alternative, the method utilizes two main compositions. The first composition is Soma, a healing herb described in the Rig Veda, the sacred scriptures of the Hindus. The second composition is a composite of plant-derived substances and a mineral. When they are administered to cancer patients following the recommended therapeutic regimen, regression of the cancer results. Alternatively, the second composition can be used alone.

Abstract: The present invention relates to extracts from Cimicifuga species and particularly from Cimicifuga racemosa, which are suited for producing a ready-formulated drug for the selective treatment and/or prophylaxis of sexual hormone-related disorders of the uro-genital tract. The extracts in accordance with the invention are moreover suited for the treatment and/or prophylaxis of post-menopausal urinary bladder infections. They are furthermore indicated for the treatment of benign and malignant prostate hyperplasies.

Abstract: The invention features isolated cytochrome P450 polypeptides and nucleic acid molecules, as well as expression vectors and transgenic plants containing these molecules. In addition, the invention features uses of such molecules in methods of increasing the level of resistance against a disease caused by a plant pathogen in a transgenic plant, in methods for producing altered compounds, for example, hydroxylated compounds, and in methods of producing isoprenoid compounds.

Abstract: Human monoclonal antibodies and fragments thereof which bind, neutralize and provide passive immunotherapy to respiratory syncytial virus (RSV) antigenic subgroups A and B are disclosed. Also disclosed are diagnostic and immunotherapeutic methods of using the monoclonal antibodies as well as cell line producing the monoclonal antibodies.

Abstract: One embodiment of the invention is demineralized bone putty composition comprises: (1) demineralized bone matrix (DBM); and (2) a lipid fraction selected from the group consisting of lecithin and a mixture of lecithin and triglycerides containing unsaturated fatty acids. The putty composition is moldable, biocompatible, slowly resorbable, insoluble in tissue fluids, and non-extrudable. The composition delivers a biologically active product to animals and humans that will enhance bone formation at sites where bone is lost, deficient, or present in suboptimal amounts. The composition can further comprise calcium, an antioxidant such as Vitamin E or Vitamin C, or a hydrophilic polymer such as methylcellulose, a methylcellulose derivative, carboxymethyl cellulose, or hydroxypropyl methylcellulose.

Abstract: Zinc finger-nucleotide binding polypeptides having binding specificity for target nucleotides containing one or GNN triplets are provided. Compositions containing such polypeptides and the use of such polypeptides and compositions for regulating gene expression are also provided.

Abstract: A urethral suppository comprising a non-meltable base member sized to prevent insertion of the base member into the urethra, a non-meltable reinforcement projecting from the base member, and a meltable portion formed around a portion of the reinforcement. The meltable portion tapers along the reinforcement and is shaped for cooperating with the action of the periurethral musculature to retain the suppository within the urethra. A method of delivering one or more therapeutic agents to the female urinary tract, the method involving insertion of the urethral suppository into the urethra. A method for manufacturing a reinforced urethral suppository.

Abstract: A new method is described for the treatment of cancer. In one alternative, the method utilizes two main compositions. The first composition is Soma, a healing herb described in the Rig Veda, the sacred scriptures of the Hindus. The second composition is a composite of plant-derived substances and a mineral. When they are administered to cancer patients following the recommended therapeutic regimen, regression of the cancer results. Alternatively, the second composition can be used alone.

Abstract: The invention features plant cells and plants that include a nucleic acid molecule encoding a chimeric isoprenoid synthase polypeptide including an asymmetrically positioned homologous domain. The chimeric isoprenoid synthases of the invention catalyze the production of isoprenoid reaction products that are not produced when the asymmetrically positioned homologous domain is positioned at its naturally-occurring site in an isoprenoid synthase polypeptide.

Abstract: The present invention provides an assay for the identification of agents which can modulate TOR-mediated phosphorylation of substrate proteins. The assays of the invention utilize substrate proteins whose amino acid sequence contains the Ser/Thr motif recognized by TOR. Naturally occurring TOR which may be used in the methods of the invention include TOR isolated from a variety of species, particularly mammalian tissues.

Abstract: Polypeptides that contain from 2 to 12 zinc finger-nucleotide binding regions that bind to nucleotide sequences of the formula (ANN)2–12 are provided. Polynucleotides that encode such polypeptides and methods of regulating gene expression with such polypeptides and polynucleotides are also provided.

Abstract: A system that includes a container containing a fluid, a fluid line coupled with the container, and a pump configured to pump the fluid out of the container through the fluid line. The system further includes a sensor that includes a wireless transmitter. The sensor is configured to sense the pressure in the fluid line and to periodically transmit, using the wireless transmitter, an alarm message when the pressure reaches an alarm threshold.